Position in FBIO
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$934,734
+$82,476 QoQ
Shares Held
305,469
0.0% QoQ
Ownership
0.834%
of shares outstanding
% of Portfolio
0.29%
of 13F equity value
Holder Rank
#1
of 9 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SHIKIAR ASSET MANAGEMENT INC holds $26,063,838 across 6 Biotechnology names. FBIO ranks #4 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
92,875 | $10,528,310 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
14,950 | $8,027,402 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
33,205 | $6,218,632 | |
| 4 | FBIO |
Fortress Biotech, Inc.
This page
|
305,469 | $934,734 | |
| 5 | URGN |
UroGen Pharma Ltd.
|
8,750 | $322,000 | |
| 6 | ALLO |
Allogene Therapeutics, Inc.
|
15,750 | $32,760 |
All Filings in FBIO
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $934,734 | 305,469 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $852,258 | 305,469 | Shares | Sole | 2026-04-23 | |
| 2025-12-31 | $1,019,195 | 278,469 | Shares | Sole | 2026-01-22 | |
| 2025-09-30 | $1,030,335 | 278,469 | Shares | Sole | 2025-10-14 | |
| 2025-06-30 | $517,951 | 278,469 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $368,110 | 235,969 | Shares | Sole | 2025-04-17 | |
| 2024-12-31 | $479,017 | 235,969 | Shares | Sole | 2025-01-15 | |
| 2024-09-30 | $342,155 | 235,969 | Shares | Sole | 2024-10-10 | |
| 2024-06-30 | $386,406 | 225,969 | Shares | Sole | 2024-07-16 | |
| 2024-03-31 | $446,272 | 223,136 | Shares | Sole | 2024-04-22 | |
| 2023-12-31 | $551,239 | 183,136 | Shares | Sole | 2024-02-01 | |
| 2023-09-30 | $332,195 | 1,145,500 | Shares | Sole | 2023-10-31 | |
| No filing history on record for this holder in this stock. | ||||||